Glenn Sblendorio Named Chairman of ARTHEx Biotech Board
News related to:ARTHEx Biotech · 1 min read
VALENCIA, Spain, Sept. 29, 2026 /CourierPR/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, has appointed Glenn P. Sblendorio as its new Chairman of the Board. Sblendorio, an experienced biotechnology executive with over three decades of leadership in corporate strategy, finance, and business development, brings a wealth of expertise to the role. His appointment comes at a critical time for ARTHEx, as the company advances its lead program, ATX-01, through clinical development.
ATX-01 is being evaluated for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder. The company's proprietary platform, BOOST-ON™, is designed to reach skeletal muscle, heart, and brain, supporting the development of therapies that address the multisystem nature of diseases such as DM1.
Glenn Sblendorio is an accomplished biotechnology executive with extensive experience in executive and board leadership, finance, accounting, and business development. Prior to his role at IVERIC bio, Inc., he served as CEO and was previously President and Chief Financial Officer of The Medicines Company. Before that, he was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc., until it was acquired by OSI Pharmaceuticals, Inc. Prior to his tenure at Eyetech, Sblendorio was a Managing Director of MPM Capital Advisors. He currently serves as Chair of the Board of Directors of Mineralys Therapeutics, Inc., and as a member of the Board of Directors of Amicus Therapeutics, Inc. (acquired by Biomarin) and ARTHEx.
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ON™, pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and brain. The company's lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases.